← All trials
NCT04512963
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 24, 2020
- Primary completion
- Feb 6, 2021
- Completion date
- Feb 14, 2021
- First posted
- Aug 14, 2020
- Last posted
- Oct 29, 2020
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- PRG Science & Technology Co., Ltd.Lead sponsor
- Amarex Clinical ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.